Archive:disease modifying

• Aducanumab (AduhelmTM) – the first disease-modifying treatment for Alzheimer’s disease approved by the US Food and Drug Administration, 7 June 2021

  Availability of Aduhelm remains unclear Coverage by Medicare and other third-party payers unknown More information to follow R. Scott Turner, PhD, MD, and the Memory Disorders Program On

  Category: News Tags: Aducanumab, Alzheimer's disease, alzheimers, disease modifying, FDA, news, treatment